Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Meta Expands AI Training With Employee Activity Tracking Tools 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
BOSTON, March 01, 2016 -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a pure-play biosimilar company focused on the development and commercialization of biosimilar monoclonal antibodies (mAbs), today announced it will release its fourth quarter and fiscal year 2015 financial results on Tuesday, March 15, 2016. In conjunction with the release, the Company has scheduled a conference call and webcast on Tuesday, March 15, 2016 at 8:00 a.m. ET to discuss the financial results and provide a business update.
Conference Call Information
When: Tuesday, March 15, 2016, 8:00 a.m. ET
Dial-in: 1-855-638-3957 (United States) or 1-224-633-1318 (International)
Conference ID: 58250825
Webcast: http://ir.epirusbiopharma.com/events.cfm
Please join the conference call at least 10 minutes early to register.
The webcast will be archived on EPIRUS' website for a period of three months.
About EPIRUS Biopharmaceuticals
EPIRUS Biopharmaceuticals (Nasdaq:EPRS) is a pure-play biosimilar company focused on the global development and commercialization of biosimilar monoclonal antibodies (mAbs). EPIRUS' goal is to improve global patient access to important, cost-effective medicines. The company’s current pipeline of biosimilar product candidates includes: BOW015 (infliximab, reference biologic Remicade®), currently marketed outside the U.S. and in an ongoing global Phase 3 study for registration in Europe and North America; BOW050 (adalimumab, reference biologic Humira®); BOW070 (tocilizumab, reference biologic Actemra®); BOW080 (eculizumab, reference biologic Soliris®); BOW090 (ustekinumab, reference biologic STELARA®); and BOW100 (golimumab, reference biologic SIMPONI®)i. The reference products for these candidates together generated approximately $29.2 billion in global sales for 2014, according to EvaluatePharma®. EPIRUS has established multiple partnerships to support its regulatory and commercialization efforts in global markets.
i. Remicade is a registered trademark of Johnson and Johnson; Humira is a registered trademark of AbbVie; Actemra is a registered trademark of Chugai Seiyaku Kabushiki Kaisha Corp., a member of the Roche Group; Stelara is owned and marketed by Centocor Ortho Biotech Inc, a wholly owned subsidiary of Johnson and Johnson; Simponi is marketed by Janssen Biotech Inc; Soliris is a registered trademark of Alexion Pharmaceuticals, Inc.
Contact Information For investor inquiries: Marek Ciszewski, J.D., EPIRUS Biopharmaceuticals +1-617-553-9716 [email protected] For media inquiries: Hope Buggey, FleishmanHillard +1-919-336-3786 [email protected]
